High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma:: comparison with biochemical determination in a prospective study of 793 cases

被引:96
作者
Zafrani, B
Aubriot, MH
Mouret, E
de Crémoux, P
de Rycke, Y
Nicolas, A
Boudou, E
Vincent-Salomon, A
Magdelénat, H
Sastre-Garau, X
机构
[1] Inst Curie, Dept Pathol, F-75248 Paris 05, France
[2] Inst Curie, Dept Biostat, F-75248 Paris, France
[3] Inst Curie, Dept Pathophysiol & Pharmacol, F-75248 Paris 05, France
关键词
biochemical assay; breast carcinoma; hormone receptors; immunohistochemistry;
D O I
10.1046/j.1365-2559.2000.01006.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: The hormone receptor (HR) status of breast cancer is an important prognostic factor and predictive parameter of the response to hormone therapy. Enzyme immunoassay (EIA) is currently the standard for determination of HR, but immunohistochemistry (IHC) represents a potentially useful alternative. We used IHC to determine HR status in a large prospective study and compared the results to those obtained by ETA, This study was designed to determine which technique should be used in daily practice in our institution which manages a large number of patients. Methods and results: Oestrogen (ER) and progesterone (PgR) receptor status was evaluated in a prospective series of 793 infiltrating breast cancers by IHC in paraffin-embedded tissue sections, using antibodies 6F11 and 1A6, with a rigorous quality control of the methodology. ER were found to be significantly expressed in 81% of cases after IHC analysis and in 78% of cases by EIA. For PgR, the respective rates of positivity were 65% and 69%. The tumour BR level detected by either technique was significantly correlated with the value of tumour size, histological grade and S-phase fraction. A significant link was observed between the percentage of labelled cells after II-IC analysis and the amount of protein detected by EIA. Critical analysis of discordance found that, in the group of invasive lobular carcinomas, the rate of IIR positivity was higher with IHC (84%) than with EIA (45%) and that, in the overall population, IHC was more specific than EIA, since cases with nonrelevant positivity related to intraductal normal or neoplastic cells expressing Im could be discarded, The cost of IHC analysis was found to be about one-third of that of EIA, Conclusions: IHC is more sensitive, specific and economical than EIA. It should constitute the new standard technique provided that good quality assurance procedures are respected.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 31 条
[1]  
Alberts SR, 1996, CANCER-AM CANCER SOC, V78, P764
[2]  
ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107
[3]   ESTROGEN-RECEPTOR IN PRIMARY BREAST-CANCER ESTIMATED IN PARAFFIN-EMBEDDED TISSUE - A STUDY OF ITS USEFULNESS COMPARED TO DEXTRAN-COATED CHARCOAL ASSAY [J].
ANDERSEN, J ;
THORPE, SM ;
ROSE, C ;
CHRISTENSEN, I ;
RASMUSSEN, BB ;
POULSEN, HS .
ACTA ONCOLOGICA, 1991, 30 (06) :685-690
[4]   DETERMINATION OF ESTROGEN-RECEPTORS IN PARAFFIN-EMBEDDED TISSUE - TECHNIQUES AND THE VALUE IN BREAST-CANCER-TREATMENT [J].
ANDERSEN, J .
ACTA ONCOLOGICA, 1992, 31 (06) :611-627
[5]   Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance [J].
Barnes, DM ;
Millis, RR ;
Beex, LVAM ;
Thorpe, SM ;
Leake, RE .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) :1677-1682
[6]  
BARNES DM, 1996, BRIT J CANCER, V74, P716
[7]  
Battifora H, 1993, APPL IMMUNOHISTO M M, V1, P39
[8]  
Bevitt DJ, 1997, J PATHOL, V183, P228
[9]  
Biesterfeld S, 1997, ANTICANCER RES, V17, P4723
[10]   IDENTIFICATION OF THE MAJOR SOURCES OF ERROR IN ESTROGEN-RECEPTOR MEASUREMENTS FOR INDIVIDUAL LABORATORIES USING BOTH TISSUE AND CYTOSOL SAMPLES [J].
BORJESSON, BW ;
CAUCHI, MN ;
COMPTON, PJ ;
FOO, TMS ;
GRAMACHO, C ;
HAHNEL, R ;
HO, KP ;
HOLDAWAY, IM ;
HORSFALL, DJ ;
LIE, TH ;
LENTERN, JM ;
LEWIS, JG ;
MCGINLEY, R ;
MILLIKEN, J ;
PEARCE, P ;
PITSIAVAS, V ;
SMYTH, C ;
SPEED, JF ;
WYATT, B .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (07) :1079-1086